| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Sodium Danshensu (Danshensu Sodium), the sodium salt of danshensu, is a novel, potent, naturally occuring phenolic acid of caffeic acid derivatives isolated from Salvia miltiorrhiza with various biological activity (e.g, antioxidant, anti-inflammatory). Sodium Danshensu is a mono sodium of danshensu which is a compound isolated from Salvia miltiorrhiza Bge. Danshensu is an efficient radical scavenger and antioxidant which exhibits higher scavenging activities against free hydroxyl radicals, superoxide anion radicals.
| Targets |
Natural product; CYP2E1 (IC50 = 12.6 μM); NF-κB
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
Danhong Injection (DHI) as a Chinese patent medicine is mainly used to treat ischemic encephalopathy and coronary heart disease in combination with other chemotherapy. However, the information on DHI's potential drug interactions is limited. The goal of this work was to examine the potential P450-mediated metabolism drug interaction arising from DHI and its active components. The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. Danshensu and rosmarinic acid inhibited CYP2E1 and CYP2C9 with IC50 values of 36.63 and 75.76 μm, and 34.42 and 76.89 μm, respectively. Salvianolic acid A and B inhibited CYP2D6, CYP2E1 and CYP2C9 with IC50 values of 33.79, 21.64 and 31.94 μm, and 45.47, 13.52 and 24.15 μm, respectively. The study provides some useful information for safe and effective use of DHI in clinical practice[3].
|
|
| Cell Assay |
By substituting medium with an "ischemic buffer," which is made to mimic the extracellular environment of myocardial ischemia and contain concentrations of potassium, hydrogen, and lactate ions that are similar to those found in vivo, cardiomyocytes are subjected to ischemia. A humidified atmosphere with 5% CO2 and 95% nitrogen is used to incubate cells in the hypoxic/ischemic chamber for two hours at 37°C. Cardiomyocytes are randomly exposed to one of the following therapies at the start of reperfusion: vehicle, Danshensu (1 or 10 μM), Danshensu plus the PI3K inhibitor wortmannin (10 nM), or Danshensu plus the ERK inhibitor U0126 (10 μM). H9c2 cardiomyocytes are cultured normally in CO2 incubation for the control group's cardiomyocytes at the same time.
|
|
| Animal Protocol |
Paeonol (80 mg kg(-1)) and danshensu (160 mg kg(-1)) were administered orally to Sprague Dawley rats in individual or in combination for 21 days. At the end of this period, rats were administered isoproterenol (85 mg kg(-1)) subcutaneously to induce myocardial injury. After induction, rats were anaesthetized with pentobarbital sodium (35 mg kg(-1)) to record electrocardiogram, then sacrificed and biochemical assays of the heart tissues were performed. Principal findings: Induction of rats with isoproterenol resulted in a marked (P<0.001) elevation in ST-segment, infarct size, level of serum marker enzymes (CK-MB, LDH, AST and ALT), cTnI, TBARS, protein expression of Bax and Caspase-3 and a significant decrease in the activities of endogenous antioxidants (SOD, CAT, GPx, GR, and GST) and protein expression of Bcl-2. Pretreatment with paeonol and danshensu combination showed a significant (P<0.001) decrease in ST-segment elevation, infarct size, cTnI, TBARS, protein expression of Bax and Caspase-3 and a significant increase in the activities of endogenous antioxidants and protein expression of Bcl-2 and Nrf2 when compared with individual treated groups.[4]
|
|
| References |
[1]. Food Chem Toxicol.2008 Jan;46(1):73-81;
[2]. Toxicol Mech Methods.2010 Oct;20(8):510-4. [3]. Biomed Chromatogr. 2018 Aug;32(8):e4250. [4]. PLoS One. 2012;7(11):e48872. |
|
| Additional Infomation |
Sodium danshensu is a monocarboxylic acid and a member of benzenes.
|
| Molecular Formula |
C9H9O5.NA
|
|
|---|---|---|
| Molecular Weight |
220.15
|
|
| Exact Mass |
220.034
|
|
| Elemental Analysis |
C, 49.10; H, 4.12; Na, 10.44; O, 36.34
|
|
| CAS # |
67920-52-9
|
|
| Related CAS # |
Danshensu;76822-21-4;(Rac)-Salvianic acid A;23028-17-3
|
|
| PubChem CID |
23711819
|
|
| Appearance |
White to off-white solid powder
|
|
| LogP |
-0.3
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
15
|
|
| Complexity |
211
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
ZMMKVDBZTXUHFO-UHFFFAOYSA-M
|
|
| InChi Code |
InChI=1S/C9H10O5.Na/c10-6-2-1-5(3-7(6)11)4-8(12)9(13)14;/h1-3,8,10-12H,4H2,(H,13,14);/q;+1/p-1
|
|
| Chemical Name |
sodium;3-(3,4-dihydroxyphenyl)-2-hydroxypropanoate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 50 mg/mL (227.12 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5424 mL | 22.7118 mL | 45.4236 mL | |
| 5 mM | 0.9085 mL | 4.5424 mL | 9.0847 mL | |
| 10 mM | 0.4542 mL | 2.2712 mL | 4.5424 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
